Groups

Groups
E-mail Print PDF

2017

Chaskar P, Zoete V, Röhrig UF.
On-the-Fly QM/MM Docking with Attracting Cavities.
J Chem Inf Model. 2017 Jan 23;57(1):73-84.


Daina A, Michielin O, Zoete V.
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.
Sci Rep. 2017 Mar 3;7:42717.


Röhrig UF, Zoete V, Michielin O.
The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 (IDO1).
Biochemistry. 2017 Aug 22;56(33):4323-4325.


Daina A, Blatter MC, Baillie Gerritsen V, Palagi PM, Marek D, Xenarios I, Schwede T, Michielin O, Zoete V
Drug Design Workshop: A Web-Based Educational Tool To Introduce Computer-Aided Drug Design to the General Public
J. Chem. Educ., 2017, 94(3):335-344.


Merkle PS, Irving M, Hongjian S, Ferber M, Jørgensen TJD, Scholten K, Luescher I, Coukos G, Zoete V, Cuendet MA, Michielin O, Rand KD.
The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed ~2-Microglobulin through Distinct Binding Sites.
Biochemistry. 2017 Aug 1;56(30):3945-3961.


Crippa S, Ancey PB, Vazquez J, Angelino P, Rougemont AL, Guettier C, Zoete V, Delorenzi M, Michielin O, Meylan E.
Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma.
EMBO Mol Med. 2017 Nov;9(11):1589-1604.


Ansar M, Riazuddin S, Sarwar MT, Makrythanasis P, Paracha SA, Iqbal Z, Khan J, Assir MZ, Hussain M, Razzaq A, Polla DL, Taj AS, Holmgren A, Batool N, Misceo D, Iwaszkiewicz J, de Brouwer APM, Guipponi M, Hanquinet S, Zoete V, Santoni FA, Frengen E, Ahmed J, Riazuddin S, van Bokhoven H, Antonarakis SE.
Biallelic variants in LINGO1 are associated with autosomal recessive intellectual disability, microcephaly, speech and motor delay.
Genet Med. 2017 Aug 24. doi: 10.1038/gim.2017.113. [Epub ahead of print]


Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, Cabello E, Homicsko K, Michielin O, Hanahan D, Speiser DE, Swartz MA.
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.
Sci Transl Med. 2017 Sep 13;9(407).


Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Cell. 2017 Sep 7;170(6):1109-1119.e10.


Harrington KJ, Michielin O, Malvehy J, Pezzani Grüter I, Grove L, Frauchiger AL, Dummer R.
A practical guide to the handling and administration of talimogene laherparepvec in Europe.
Onco Targets Ther. 2017 Aug 2;10:3867-3880. doi: 10.2147/OTT.S133699. eCollection 2017. Review.


Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R.
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Melanoma Res. 2017 Aug;27(4):358-368.


Dummer R, Hoeller C, Gruter IP, Michielin O.
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Cancer Immunol Immunother. 2017 Jun;66(6):683-695.


Spodzieja M, Lach S, Iwaszkiewicz J, Cesson V, Kalejta K, Olive D, Michielin O, Speiser DE, Zoete V, Derré L, Rodziewicz-Motowid~o S.
Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
PLoS One. 2017 Jun 8;12(6):e0179201.


 

google analytics